Orchestra BioMed Holdings Inc Ordinary Shares OBIO 深 沪
等待开盘 08-27 09:30:00 美东时间
3.00
+0.400
+15.38%
华盛通- 最 高3.0799
- 今 开2.66
- 成交量 94.34万股
- 最 低 2.635
- 昨 收 2.60
- 总市值 1.15亿
- 52周最高 6.50
- 市盈率 静 --
- 换手率 2.46%
- 52周最低 2.37
- 委 比 48.86%
- 总股本 3831.25万
- 历史最高 23.39
- 量 比 3.59
- 振 幅 17.11%
- 历史最低 2.37
- 每 手 1
- 风险率 1.40%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Orchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical Electrophysiology
Orchestra BioMed announced positive data from a pressure-volume loop study showing AVIM therapy effectively reduces systolic blood pressure and improves cardiovascular hemodynamics in pacemaker-indicated patients with uncontrolled hypertension. The therapy demonstrated significant reductions in blood pressure, cardiac workload, and intra-cardiac volumes without adverse effects on stroke volume. Published in JACC: Clinical Electrophysiology, the s...
08-26 11:30
BTIG Downgrades Orchestra BioMed Hldgs to Neutral
BTIG analyst Marie Thibault downgrades Orchestra BioMed Hldgs (NASDAQ:OBIO) from Buy to Neutral.
08-20 19:20
Orchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and Diastolic Dysfunction
AvIM Therapy Shows Promise in Treating Hypertension and Diastolic Dysfunction. MODERATO II study demonstrates significant reductions in systolic blood pressure and improvements in cardiac function in patients with hypertension and diastolic dysfunction, a key contributor to heart failure with preserved ejection fraction (HFpEF). The study highlights the potential of AVIM therapy to address unmet medical needs in managing hypertensive heart diseas...
08-14 12:00
Orchestra BioMed Hldgs Q2 EPS $(0.50) Beats $(0.51) Estimate, Sales $836.000K Beat $695.600K Estimate
Orchestra BioMed Hldgs (NASDAQ:OBIO) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $(0.51) by 0.99 percent. This is a 11.11 percent decrease over losses of $(0.45) per share
08-12 20:17
Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates
Orchestra BioMed announced Q2 2025 financial results, including $111.2 million in gross proceeds from strategic transactions and equity offerings, FDA regulatory milestones for AVIM therapy and Virtue SAB, expanded BACKBEAT study enrollment, and a $101 million cash position.
08-12 12:14
Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility
Orchestra BioMed has expanded eligibility criteria for its BACKBEAT study, increasing the potential patient pool by over 24-fold. The updated protocol includes patients with Medtronic Astra or Azure pacemakers, those receiving device replacements, and those with NYHA I or II heart failure. This aligns the study with FDA Breakthrough Device Designation for AVIM therapy, targeting millions of U.S. patients with uncontrolled hypertension. The update...
08-08 11:00
Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings
Orchestra BioMed Holdings, Inc. announced the successful completion of strategic transactions and concurrent public and private equity offerings totaling $111.2 million in gross proceeds to support the advancement of its late-stage AVIM therapy and Virtue SAB clinical programs. The proceeds include $56.2 million from a public offering and private placements, and $55 million in royalty-based investments from Medtronic and Ligand. The funds are exp...
08-05 11:00
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers 4D Molecular Therapeutics (NASDAQ:FDMT) shares moved upwards by 33.1% ...
08-01 05:07
Orchestra BioMed Secures $70M for Cardiology Programs
Orchestra BioMed Holdings ( ($OBIO) ) has issued an update. On July 31, 2025, O...
08-01 04:49
Orchestra BioMed Announces Proposed Public Offering; No Size Or Amount Disclosed
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company"))), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, announced today that
08-01 04:03
